Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESO-T01 in Relapsed/Refractory Multiple Myeloma
NCT06791681Phase 1Recruiting
- Start
- Jan 2025
- Primary completion
- Nov 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ESO-T01 in multiple myeloma (MM). Primary endpoints: Dose-limiting toxicities at 28 days, Cytokine release syndrome at 28 days and 2 more. Started Jan 2025; status: recruiting.
02
Drugs
ESO-T01
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06791681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06791681.